Roivant’s inhaled pulmonary hypertension drug mosliciguat shows strong Phase 2 results

Roivant invested $14 million in Bayer's inhaled soluble guanylate cyclase activator mosliciguat after a $294 million biobucks agreement in 2024, and promptly advanced the candidate into a Phase 2 study.

The PHocus trial enrolled 135 patients with pulmonary hypertension linked to interstitial lung disease across 20 countries. At Week 16 the drug achieved a 56.3% placebo‑adjusted reduction in pulmonary vascular resistance, meeting the primary endpoint.

Secondary measures also succeeded, with a 35.2‑meter improvement in six‑minute walk distance and a 53.2% reduction in NT‑proBNP levels. Cough was reported in 12.1% of treated participants versus 18.2% on placebo, suggesting a favorable safety profile.